Adherence to antiretroviral therapy in Africa: how high is it really?

被引：8

作者：

Jaffar, Shabbar ^{[1
]}

Munderi, Paula ^{[2
]}

Grosskurth, Heiner ^{[1
,2
]}

机构：

[1] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England

[2] MRC, Uganda Virus Res Inst, AIDS Res Unit, Entebbe, Uganda

来源：

TROPICAL MEDICINE & INTERNATIONAL HEALTH | 2008年 / 13卷 / 09期

基金：

英国医学研究理事会;

关键词：

adherence; antiretroviral; Africa; survival; RNA viral load;

D O I：

10.1111/j.1365-3156.2008.02131.x

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

引用

页码：1096 / 1097

页数：2

共 19 条

[1]

Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2

[2] Adherence to highly active antiretroviral therapy in the real world: experience of twelve English HIV units [J].

Brook, MG ;

Dale, A ;

Tomlinson, D ;

Waterworth, C ;

Daniels, D ;

Forster, G .

AIDS PATIENT CARE AND STDS, 2001, 15 (09) :491-494

[3] Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa [J].

Coetzee, D ;

Hildebrand, K ;

Boulle, A ;

Maartens, G ;

Louis, F ;

Labatala, V ;

Reuter, H ;

Ntwana, N ;

Goemaere, E .

AIDS, 2004, 18 (06) :887-895

[4] Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis [J].

Carrasco, Maria Alejandra .

CORNEA, 2008, 27 (06) :743-745

[5] Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal:: a 7-year cohort study [J].

Etard, JF ;

Ndiaye, I ;

Thierry-Mieg, M ;

Guèye, NFN ;

Guèye, PM ;

Lanièce, I ;

Dieng, AB ;

Diouf, A ;

Laurent, C ;

Mboup, S ;

Sow, PS ;

Delaporte, E .

AIDS, 2006, 20 (08) :1181-1189

[6]

GAZZARD B, 2005, HIV MED S, V6, pS61

[7] No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa [J].

Gill, CJ ;

Hamer, DH ;

Simon, JL ;

Thea, DA ;

Sabin, LL .

AIDS, 2005, 19 (12) :1243-1249

[8]

Jaffar S, 2004, B WORLD HEALTH ORGAN, V82, P462

[9] Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa [J].

Kaleebu, P. ;

Pillay, D. ;

Walker, A. S. ;

Robertson, V. ;

Gale, C. V. ;

Enzama, R. ;

Yirrell, D. ;

Lyagoba, F. ;

Kityo, C. ;

Munderi, P. ;

Reid, A. ;

Gibb, D. M. ;

Bray, D. ;

Burke, A. ;

Ait-Khaled, M. ;

Darbyshire, J. H. ;

Muygenyi, P. ;

Hakim, J. ;

Grosskurth, H. ;

Gilks, C. ;

Enzama, R. ;

Tugume, S. ;

Chirara, M. ;

Lyagoba, F. ;

Gale, C. ;

Mugyenyi, P. ;

Kityo, C. ;

Ssali, F. ;

Tumukunde, D. ;

Otim, T. ;

Namale, L. ;

Mukose, A. ;

Muhwezi, A. ;

Kabuye, G. ;

Mulindwa, G. ;

Atwine, D. ;

Kyomugisha, H. ;

Drasiku, A. ;

Tumusiime, C. ;

Sabiiti, J. ;

Zawedde, C. ;

Komugyena, J. ;

Okiror, J. ;

Byaruhanga, R. ;

Ocitti, P. ;

Grace, T. Bakainyaga ;

Katabira, H. ;

Barungi, G. ;

Masiira, D. ;

Atwine, A. .

AIDS, 2006, 20 (10) :1391-1399

[10] Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America [J].

Keiser, Olivia ;

Anastos, Kathryn ;

Schechter, Mauro ;

Balestre, Eric ;

Myer, Landon ;

Boulle, Andrew ;

Bangsberg, David ;

Toure, Hapsatou ;

Braitstein, Paula ;

Sprinz, Eduardo ;

Nash, Denis ;

Hosseinipour, Mina ;

Dabis, Francois ;

May, Margaret ;

Brinkhof, Martin W. G. ;

Egger, Matthias .

TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (07) :870-879

← 1 2 →